Experimental drug rigosertib tested against aggressive skin cancer in rare disease patients
NCT ID NCT03786237
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small early-phase trial tested an experimental drug called rigosertib in just 2 people with a rare blistering skin disease (recessive dystrophic epidermolysis bullosa) who also had advanced skin cancer. The goal was to see if the drug could shrink tumors and whether it was safe. Rigosertib was given as oral capsules or intravenous infusions. Because only 2 patients took part, the results are very limited and cannot be generalized.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rigosertib (oral capsules or intravenous infusion)
- What this could lead to
- If it works, this could point toward a treatment for advanced skin cancer in people with recessive dystrophic epidermolysis bullosa.
- What could go wrong
- This is a very small, early-phase trial with only 2 patients, so results may not apply to others. The drug may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA DYSTROPHICA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
EB House Austria/Dept. of Dermatology University Hospital
Salzburg, State of Salzburg, 5020, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Glowing cancer cells: a new way to see tumors during surgery?
- Botox before the knife: could a Pre-Surgery injection lead to Better-Looking scars?
- Immunotherapy before surgery may cut skin cancer recurrence
- Mouth rinse could ease painful radiation side effects for head and neck cancer patients
- New skin patch could speed recovery after skin cancer removal